Albumax Has Been Approved By Medicaid in New York
Medivisor, Inc. (PINKSHEETS: MVSR) announced today that Albumax has been approved by the New York State Medicaid Office. Albumax has been approved under code B4155 as an enteral product. The approval is significant in that it allows for Medicaid reimbursement of costs for eligible patients using Albumax. Medicaid is the largest source of funding for medical and health-related services for people with limited income. It is an entitlement program that is jointly funded by the states and federal government, and is managed by the states. Among the groups of people served by Medicaid are eligible low-income parents, children, seniors, and people with disabilities.
“Medicaid approval is an extremely important component in our marketing initiative for the national launch of Albumax,” said Mr. Dino Luzzi, CEO of Medivisor, Inc. “Medicaid acceptance for Albumax certainly strengthens the interest in the product, and increases the willingness of providers and patients to use Albumax to increase blood albumin levels in kidney disorder patients,” continued Mr. Luzzi. An important component of the overall initiative for Albumax is a very aggressive Internet marketing program that consistently keeps Albumax in the marketplace. Patients and those in the Medical Profession can now go to www.albumax.net to order or inquire about the product.
Under a recently announced agreement with Cura Pharmaceutical Co., Inc., Medivisor is responsible for marketing and sales of Albumax, a whey protein isolate formula that makes it easy for kidney disorder patients to reach their daily requirements of high quality protein in their diet.
About Medivisor, Inc.
Medivisor, Inc., a rapidly growing developer of next-generation focus driven marketing tools. The company is dedicated to providing technologies that offer innovative and competitive advantages to the bioscience and pharmaceutical markets and beyond. From pre-product development through product launch and commercialization, Medivisor offers worldwide experience in delivering effective and successful integrated marketing and creative communications campaigns for the mutual benefit of its clients. www.medivisor.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”) Additionally, words such as “seek,”"intend,”"believe,”"plan,”"estimate,”"expect,”"anticipate” and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the performance ability of the initial units in the field. Further information on Medivisor risk factors is contained in its filings with the Securities and Exchange Commission. Medivisor does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Contact: Dino Luzzi CEO Medivisor, Inc. 326 Walt Whitman Road Huntington Station, N.Y. 11746 Tel: 631.549.7100 http://www.medivisor.com
SOURCE: Medivisor, Inc.